Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

Journal of Clinical Oncology

Volumn 13, Issue 9, 1995, Pages 2196-2207

  Kobayashi, Ken ^a   Vokes, Everett E ^b   Vogelzang, Nicholas J ^b   Janisch, Linda ^b   Soliven, Betty ^b   Ratain, Mark J ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; HYDROCORTISONE; PROSTATE SPECIFIC ANTIGEN; SURAMIN; VITAMIN K GROUP;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALAISE; MALE; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0029120379     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.9.2196     Document Type: Article

References (35)

1. Armand JP, Bonnay M, Gandia D, et al: Phase I-II Suramin (SRM) study in advanced cancer patients (pts). Proc Am Assoc Cancer Res 32:175, 1991 (abstr)
2. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
3. Stein CA, LaRocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989
4. van Oosterom AT, De Smedt EA, Denis LJ, et al: Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated disease. Eur J Cancer 26:422, 1990
5. LaRocca RV, Meer J, Gilliatt RW, et al: Suramin-induced polyneuropathy. Neurology 40:954-960, 1990
6. Collins JM, Klecker RW, Yarchoan R, et al: Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26:22-26, 1986
7. Kobayashi K, Jodrell DI, Ratain MJ: Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 17:51-78, 1993
8. Kobayashi K, Vokes EE, Stefansson K, et al: Suramin: Is adaptive control necessary? J Clin Oncol 10:1984-1985, 1992 (letter)
9. Jodrell DI, Reyno LM, Sridhara R, et al: Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentrations in patients with prostate cancer. J Clin Oncol 12:166-175, 1994
10. Bourne DW: BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed 29:191-195, 1989
11. Tong WP, Scher HI, Petrylak DP, et al: A rapid assay of suramin in plasma. J Liq Chromatogr 13:2269-2284, 1990
12. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
13. von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
14. Norusis MJ: SPSS for Windows User's Guide. Chicago, IL, SPSS Inc, 1993
15. Rago RP, Miles JM, Surit RL, et al: Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Cancer 73:1954-1959, 1994
16. Katz SK, Medenica MM, Kobayashi K, et al: Erythema multiforme induced by suramin. J Am Acad Dermatol 32:292-3, 1994
17. Kobayashi K, Pezen DS, Vogelzang NJ, et al: Keratoacanthomas and skin neoplasms associated with suramin. Arch Dermatol (in press)
18. Weiss RE, Kobayashi K, Ratain MJ, et al: The chronic effect of Suramin (S) on adrenal function: impaired glucocorticoid and mineralocorticoid reserve. Proceedings of the Endocrine Society, Anaheim, CA, June 15-18, 1994, p 289
19. LaRocca RV, Stein CA, Danesi R, et al: A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67:1509-1513, 1991
20. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J Natl Cancer Inst 85:611-621, 1993
21. Kobayashi K, Vokes EE, Ratain MJ: A population pharmacokinetic study of suramin (SUR) by intermittent infusion in patients with advanced cancer (CA). Clin Pharmacol Therapeut 56:181, 1995
22. von Hoff DD, Rozencweig M, Layard M, et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med 62:200-208, 1977
23. Mather FJ, Simon RM, Clark GM, et al: A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med 8:813-823, 1989
24. Kelly WK, Scher H, Bajorin D, et al: The contribution of hydrocortisone to the observed response proportions of suramin. Proc Am Soc Clin Oncol 13:231, 1994 (abstr)
25. 2 prostate cancer. Proc Am Soc Clin Oncol 13:236, 1994 (abstr)
26. Woll PJ, Ranson M, Margison J, et al: Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control. Ann Oncol 5:597-600, 1994
27. Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84:38-42, 1992
28. Wade TP, Kasid A, Stein CA, et al: Suramin interferes with TGF-beta induced inhibition of human renal cell carcinoma. Proc Am Assoc Cancer Res 30:70, 1989 (abstr)
29. Cardinali M, Sartor O, Robbins K: Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest 89:1242-1247, 1992
30. Foekens JA, Sieuwerts AM, Stuurman-Smeets EMJ, et al: Pleiotropic actions of suramin on the proliferation of human breast cancer cells in vitro. Int J Cancer 51:439-444, 1992
31. Mitchen J, Rago R, Wilding G: Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. Prostate 22:75-89, 1993
32. Morocz IA, Lauber B, Schmitter D, et al: In vitro effect of suramin on lung tumour cells. Eur J Cancer 29A:245-247, 1993
33. Olivier S, Formento P, Fischel JL, et al: Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer 26:867-871, 1990
34. Pienta KJ, Isaacs WB, Vindivich D, et al: The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199-202, 1991
35. O'Donnell BP, Dawson NA, Weiss RB, et al: Suramin-induced skin reactions. Arch Dermatol 128:75-79, 1992